Zealand Pharma A/S
NASDAQ: ZEAL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Emmanuel Dulac PharmD, MBA
- Employees
- 237
- Headquarters
- Copenhagen, Denmark
- IPO year
- 2017
- Website
- https://www.zealandpharma.com
Loading ZEAL…
Loading profile data…Frequently asked questions about ZEAL
What does Zealand Pharma A/S (ZEAL) do?
Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma A/S is a biotechnology firm focused on the discovery, development, and commercialization of peptide-based medications. The company's therapeutic pipeline and marketed products primarily address gastrointestinal and metabolic diseases, as well as other niche conditions with...
Where does ZEAL trade?
Zealand Pharma A/S (ZEAL) trades on the NASDAQ Global Select.
What sector is ZEAL in?
Zealand Pharma A/S (ZEAL) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Zealand Pharma A/S?
Emmanuel Dulac PharmD, MBA is the chief executive officer of Zealand Pharma A/S (ZEAL).
Where is Zealand Pharma A/S headquartered?
Zealand Pharma A/S is headquartered in Denmark.
Does ZEAL pay a dividend?
Zealand Pharma A/S (ZEAL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ZEAL go public?
Zealand Pharma A/S (ZEAL) completed its initial public offering in 2017.
Is ZEAL an ADR?
Yes — ZEAL is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Zealand Pharma A/S reporting and dividends follow the underlying issuer.